Biomarker & Intervention Discovery
Insomnia / Sleep Disorders
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
Spontaneous remissionAcute insomnia (<3 months): 50-60% resolve spontaneously; chronic insomnia: only 20-25% spontaneous remission at 1…
Best-intervention remissionCognitive Behavioural Therapy for Insomnia (CBT-I): 70-80% response rate; 40-60% remission (normalised sleep); durable…
Gap sizeVery large — CBT-I is guideline-recommended as first-line but almost universally unavailable; medication is default
Primary barrieraccess/framing
Full remission profile →
Remission & chronicity
Spontaneous remission
Acute insomnia (<3 months): 50-60% resolve spontaneously; chronic insomnia: only 20-25% spontaneous remission at 1 year; persistent insomnia in 50-75% without treatment
Best-intervention remission
Cognitive Behavioural Therapy for Insomnia (CBT-I): 70-80% response rate; 40-60% remission (normalised sleep); durable at 6-24 months post-treatment; superior to sleep medication in long-term outcomes; digital CBT-I (Sleepio, Somryst) equivalent efficacy to in-person
Gap size
Very large — CBT-I is guideline-recommended as first-line but almost universally unavailable; medication is default
Primary barrier
access/framing
AASM and most sleep guidelines recommend CBT-I as first-line over medication for chronic insomnia; fewer than 1% of insomnia sufferers have access to a CBT-I trained therapist; digital CBT-I exists and works but is rarely prescribed; benzodiazepines and z-drugs continue to dominate prescribing despite guidelines against long-term use
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Insomnia / Sleep Disorders” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."